Connecting Labs everywhere to
rapid genomic profiling

Oncomine Solutions for solid tumor clinical research

Rely on NGS for solid tumor genomic profiling

The number of molecular biomarkers relevant for precision oncology research is rapidly growing across solid tumors, and in many cases, sequential single-gene testing methods do not yield desired results in time or for only a limited number of biomarkers.

Therefore, next-generation sequencing (NGS) has become a technology of choice in precision oncology research for genomic profiling from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy samples*.

body-biomarkers-diagram

 

Oncomine Solutions for FFPE tissue testing

Choose from Targeted to Comprehensive Solutions

  opa-arrows

Oncomine Precision Assay 50 Genes

oca-v3-arrows

Oncomine Comprehensive Assay  V3 161 Genes

oca-plus-arrow
Oncomine Comprehensive Assay Plus 517 Genes

mag-glass-icon

 

Rapid detection of relevant biomarkers for NSCLC, melanoma, colon, thyroid, and cholangiocarcinoma  and majority of biomarkers relevant in other tumor types. Rapid detection of relevant biomarkers for majority of solid tumors including breast and prostate cancer. 
HRR genes, tumor suppressor genes such as POLE  & MDM  amongst others.
Comprehensive genomic profiling (CGP) including relevant biomarkers for the majority of solid tumors including ovarian cancer, and  gene signatures including, homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI).
clock-icon

 

Turnaround time (TAT) as little as 24 hours. Turnaround time (TAT) as little as 26 hours. Turnaround time (TAT) in 3 days.
layers-icon

 

10 ngs of DNA/RNA enabling more cancer research samples to be profiled. 20 ngs of DNA/RNA enabling more cancer samples to be profiled. 20 ngs of DNA/RNA enabling more cancer samples to be profiled.

 

Oncomine Assays for
FFPE Tissue Testing

Oncomine™ assays cover biomarkers across multiple solid tumors and enable labs to choose the most efficient tool
for each tumor sample. 

button_download-infographic-1

 

oncomine-solid-tumor-ngs-soutions--cancer-type

Oncomine Solutions for Liquid Biopsy sample testing

Choose from pan-cancer and tumor specific solutions

pan-cancer-icon

Pan-cancer

Oncomine Pan-Cancer Cell-Free Assay

  • 52 genes
  • DNA and RNA
  • SNVs, CNVs, Fusions


Oncomine Precision Assay

  • 50 genes
  • DNA and RNA
  • SNVs, indels, CNVs, Fusions

 

lung-icon

Lung Cancer

Oncomine Lung Cell-Free Total Nucleic Research Assay

  • 12 genes (ALK, BRAF, EGFR, ERBB2, KRAS MAP2K1 MET, NRAS, PIK3CA, RET, ROS1, TP53)
  • DNA and RNA
  • SNVs, CNVs, fusions,

breast-icon

Breast Cancer

Oncomine Breast cfDNA Research Assay v2

  • 12 genes (AKT1, CCND1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, KRAS, PIK3CA, SF3B1, TP53)
  • DNA
  • SNVs, CNVs

colon-icon

Colon Cancer

Oncomine Colon cfDNA Assay

  • 14 genes (AKT1, APC, BRAF, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MAP2K1, NRAS, PIK3CA, MAD4, TP53)
  • DNA
  • SNVs

Oncomine Solutions for Emerging Biomarker Testing

Cancer research is increasingly focused on precision oncology approaches that rely on the detection of biomarkers.

Deeper knowledge of molecular pathways, their interactions, and fundamental understanding of cancer biology may elucidate the progression and help predict the response of future treatments.

Oncomine Solutions provide highly automated end-to-end workflows which enable oncology biomarkers detection in a broad spectrum of laboratories.

Download our Biomarker Guides and Learn about emerging biomarker testing.

 

Additional Resources

Have question or want to learn more?

Request to speak to a Thermo Fisher Scientific NGS expert below. We will be happy to answer all your question and provide a demo.

 

button_request-contact

 

For Research Use Only. Not for use in diagnostic procedures.

*Scott J et al. JCO Oncology Practice 2023 (doi:10.1200/OP.22.00611

Case Number: 53926 05/21/2024